Three separate papers on the kidney drug finerenone landed in the New England Journal of Medicine, The Lancet, and JAMA on ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves ...

KERENDIA is currently approved by the FDA for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), as well as adults with heart failure (HF) with ...

The INFINITY analysis pooled individual participant data from the phase 3 RCTs of finerenone in people with type 2 diabetes (FIDELIO-DKD and FIGARO-DKD) and without diabetes (FIND-CKD).

Finerenone reduced kidney function decline and cardiovascular-kidney events in non-diabetic CKD. Find out more from the ...

Finerenone, a revolutionary medication initially aimed at diabetic kidney disease, now shines a light of hope for countless ...

Finerenone also reduced albuminuria at month 12 by 42% and lowered the risk of kidney failure or an eGFR decline of 40% or ...

Low-dose rivaroxaban failed to cut the high cardiovascular risk in this population in a large randomized trial, contrasting ...

Dapagliflozin reduced left ventricular mass index early into treatment in patients with nondialysis-dependent CKD, regardless of disease etiology and cardiovascular history. Dapagliflozin reduces left ...

Lubiprostone preserved renal function in stage IIIb-IV CKD patients over 24 weeks without altering uremic toxin levels, suggesting a novel renoprotective mechanism. The trial demonstrated ...

Working backwards, we hypothesized that we could improve kidney function by treating constipation." To address this issue, the group conducted a multicenter Phase II clinical trial (LUBI-CKD TRIAL) at ...